1 Report Overview
1.1 Global Tuberculosis Treatment Drugs Market Overview
1.1.1 Global Tuberculosis Treatment Drugs Market Overview
1.1.2 Why You Should Read This Report
1.1.3 How This Report Delivers
1.1.4 Key Questions Answered by This Analytical Report
1.1.5 Who is This Report For?
1.1.6 Methodology
1.1.7 Frequently Asked Questions (FAQ)
1.1.8 Associated Visiongain Reports
1.1.9 About Visiongain
2 Tuberculosis (TB) Disease Background
2.1 Disease Definition
2.2 Transmission of TB
2.2.1 Factors that Determine the Probability of M. tuberculosis Transmission
2.2.2 Characteristics of TB patient associated with Infection
2.2.3 Environmental Factors that enhance the probability that M. tuberculosis will Be transmitted
2.3 Patient Subtypes
2.3.1 Latent TB (TB infection)
2.3.2 Active TB (TB disease)
2.3.3 Difference between Latent TB Infection (LTBI) and active TB Disease
2.4 Tuberculosis Symptoms
2.4.1 On the basis of Signs and Symptoms, TB can be further Classified into: -
2.4.2 Drug-Resistant TB (MDR and XDR)
2.4.3 Multidrug-Resistant TB
2.4.4 Extensively Drug-Resistant TB
2.5 Diagnosis
2.5.1 Diagnosis of Latent tuberculosis infection (LTBI)
2.5.2 Diagnosis of Active tuberculosis infection (ATBI)
2.5.3 Guidelines for Diagnosis from the ATS, IDSA, and Control of Disease Prevention & Control (CDC)
2.5.4 Diagnostic Pipeline
2.6 Treatments for Tuberculosis
2.6.1 Anti-Tuberculosis Drugs
2.6.2 Treatment Guidelines
2.6.3 Tuberculosis Vaccine
3 Tuberculosis Epidemiology Forecast 2019-2020
3.1 World Health Organization Estimates for 2018
3.2 The Global Tuberculosis Epidemiology (2019-2030)
3.3 The United States Tuberculosis Epidemiology (2019-2030)
3.4 The Europe Tuberculosis Epidemiology (2019-2030)
3.4.1 Germany Tuberculosis Epidemiology (2019-2030)
3.4.2 France Tuberculosis Epidemiology (2019-2030)
3.4.3 Italy Tuberculosis Epidemiology (2019-2030)
3.4.4 Spain Tuberculosis Epidemiology (2019-2030)
3.4.5 The United Kingdom Tuberculosis Epidemiology (2019-2030)
3.5 Japan Tuberculosis Epidemiology (2019-2030)
3.6 ROW Tuberculosis Epidemiology (2019-2030)
3.7 30 High TB Burden Countries, 2020
4 Pipeline Drugs Analysis, 2020
4.1 Promising Therapies
4.1.1 Repurposed Drugs/Therapeutics
4.1.2 Current Regimen Trials
4.1.3 Pipeline Vaccine
5 Market Drivers & Barriers
5.1 Market Drivers Analysis
5.2 Global plan against drug-resistant TB drives diagnosis and treatment enrolment
5.3 Market Restraints Analysis
5.3.1 High Cost of Drugs
5.3.2 Poor regulation and lack of awareness in developing countries
5.4 SWOT Analysis of Tuberculosis Treatment Drugs Market
6 Global Tuberculosis Treatment Drugs Market Forecast by Regions 2019-2030
6.1 Leading Regional Markets 2020-2030
6.1.1 Geographical Breakdown of the Global Tuberculosis Drugs Market
6.1.2 Global Tuberculosis Drugs Market: Regional Forecast 2020-2030
6.1.3 How Will Regional Market Shares Change to 2030?
6.2 North America Tuberculosis Drugs Market 2020-2030
6.2.1 North America Tuberculosis Drugs Market: Forecast 2020-2030
6.3 Europe Tuberculosis Drugs Market 2020-2030
6.3.1 Europe Tuberculosis Drugs Market Forecast 2020-2030
6.4 Latin America Tuberculosis Drugs Market 2020-2030
6.4.1 Latin America Tuberculosis Drugs Market: Forecast 2020-2030
6.5 Middle East & Africa Tuberculosis Drugs Market 2020-2030
6.5.1 Middle East & Africa Tuberculosis Drugs Market: Forecast 2020-2030
6.6 Asia and Asia Pacific Tuberculosis Drugs Market 2020-2030
6.6.1 Asia and Asia Pacific Tuberculosis Drugs Market: Forecast 2020-2030
7 Global Tuberculosis Treatment Drugs Market Forecast by Therapies 2019-2030
7.1 First Line Tuberculosis Treatment Drugs Market 2019-2030
7.2 Second Line Tuberculosis Treatment Drugs Market 2019-2030
7.3 Tuberculosis Treatment Drugs Market by Therapies 2019-2030
7.3.1 Isoniazid Market Forecast 2020-2030
7.3.2 Rifampin Market Forecast 2020-2030
7.3.3 Other Drugs Market Forecast 2020-2030
8 Leading Companies in the Tuberculosis Drugs Market
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Johnson & Johnson 2019 Therapeutics
8.1.3 Latest Developments Related to Key Marketed Products
8.1.4 Johnson & Johnson, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
8.1.5 Johnson & Johnson, Revenue Forecast, 2020-2025
8.2 Lupin Limited
8.2.1 Company Overview
8.2.2 Lupin 2019 Therapeutics
8.2.3 Latest Developments Related to Key Marketed Products
8.2.4 Lupin, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
8.2.5 Lupin, Revenue Forecast, 2020-2025
8.3 Macleods Pharmaceuticals Limited
8.3.1 Company Overview
8.3.2 Macleods Pharmaceuticals Limited 2019 Therapeutics
8.3.3 Latest Developments Related to Key Marketed Products
8.3.4 Macleods Pharmaceuticals Limited, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
8.3.5 Macleods Pharmaceuticals Limited, Revenue Forecast, 2020-2025
8.4 Pfizer
8.4.1 Company Overview
8.4.2 Pfizer 2019 Therapeutics
8.4.3 Latest Developments Related to Key Marketed Products
8.4.4 Pfizer, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
8.4.5 Pfizer, Revenue Forecast, 2020-2025
8.5 Otsuka Pharmaceuticals
8.5.1 Company Overview
8.5.2 Otsuka Pharmaceuticals 2019 Therapeutics
8.5.3 Latest Developments Related to Key Marketed Products
8.5.4 Otsuka Pharmaceuticals, Tuberculosis Therapeutics- R&D Pipeline & Future Outlook
8.5.5 Otsuka Pharmaceuticals, Revenue Forecast, 2020-2025
9 Conclusions
9.1 Global Tuberculosis drugs Market in 2019, 2025 and 2030
9.1.1 Current Leading Tuberculosis Drugs Segments
9.1.2 Leading Tuberculosis drugs Companies
9.1.3 Leading Regional Markets
9.2 Global Tuberculosis Drugs Market Forecast 2020-2030
9.3 The Future of the Tuberculosis Drugs Market?
10 Associated Visiongain Reports
11 Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOS) 2020-2030
12 Visiongain Report Sales Order Form
12.1 About Visiongain
12.2 Visiongain report evaluation form
List of Tables
Table 1.1 Global Tuberculosis Treatment Drugs Market Overview, 2020-2030
Table 2.1 Key Facts about Tuberculosis
Table 2.2 Factors that Determine the Probability of Transmission of M. tuberculosis
Table 2.3 Difference between Latent TB Infection (LTBI) and TB Disease
Table 2.4 Testing of TB Infections
Table 2.5 Overview of progress in the development of TB diagnostics, August 2019
Table 2.6 Latent TB Infection Treatment Regimens
Table 2.7 Regimens for treating TB disease
Table 3.1 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.2 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.3 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.4 Germany Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.5 France Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.6 Italy Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.7 Spain Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.8 The United Kindom Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.9 Japan Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.10 ROW Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Table 3.11 30 High TB Burden Countries, 2018
Table 4.1: 2019 Global New Drug TB Pipeline
Table 4.2: 2019 Repurposed/Existing Drug TB Pipeline
Table 4.3: 2019 Clinical Regimen Trials
Table 5.1 SWOT Analysis
Table 6.1 Global Tuberculosis drug Market by Product: Revenue ($m) and Market Share (%), 2019
Table 6.2 Global Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.3 Global Tuberculosis Drugs Market By Region: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.4 Global Tuberculosis Drugs Market Forecast by Region: Revenues ($m, AGR (%), and CAGR (%), 2019-2030
Table 6.5 North America Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.6 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030
Table 6.7 United States Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.8 Canada Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.9 Europe Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.10 Europe Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.11 Germany Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.12 France Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.13 Italy Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.14 Spain Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.15 United Kingdom Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.16 Latin America Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.17 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030
Table 6.18 Brazil Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.19 Mexico Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.20 Middle East & Africa Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.21 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030
Table 6.22 South Africa Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.23 Nigeria Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.24 Asia & Asia Pacific Tuberculosis Drugs Market By Countries: Revenues ($m) and Market Share(%), 2019 and 2030
Table 6.25 Tuberculosis Drugs Market Forecast by Countries: Revenues ($m, AGR (%), and CAGR (%), 2019-2030
Table 6.26 India Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.27 China Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 6.28 China Tuberculosis drug Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 7.1 First Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 7.2 Second Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 7.3 Tuberculosis Treatment Drugs Market by Therapies: Revenues ($m) and Market Share(%), 2019 and 2030
Table 7.4 Tuberculosis Treatment Isoniazid Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 7.5 Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 7.6 Tuberculosis Treatment Other Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Table 8.1 Johnson & Johnson: Company Overview, 2019
Table 8.2 Johnson & Johnson: Products Portfolio, 2019
Table 8.3 Johnson & Johnson: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Table 8.4 Lupin: Company Overview, 2019
Table 8.5 Lupin: Products Portfolio, 2019
Table 8.6 Lupin: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Table 8.7 Macleods Pharmaceuticals Limited: Company Overview, 2019
Table 8.8 Macleods Pharmaceuticals Limited: Products Portfolio, 2019
Table 8.9 Macleods Pharmaceuticals Limited: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Table 8.10 Pfizer: Company Overview, 2019
Table 8.11 Pfizer: Products Portfolio, 2019
Table 8.12 Pfizer: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Table 8.13 Otsuka Pharmaceuticals: Company Overview, 2019
Table 8.14 Otsuka Pharmaceuticals: Products Portfolio, 2019
Table 8.15 Otsuka Pharmaceuticals: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
List of Figures
Figure 2.1 Summary of recommendations for Latent tuberculosis infection (LTBI) Testing
Table 2.2 Summary of recommendations for LTBI Testing
Figure 3.1 Global Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.2 United States Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.3 Europe Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.4 Germany Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.5 France Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.6 Italy Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.7 Spain Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.8 The United Kindom Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.9 Japan Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 3.10 ROW Tuberculosis Incidence Cases Forecast, 2019-2030 (in 000's)
Figure 4.1 2019 Global New TB vaccine Pipeline
Figure 6.1 Global Tuberculosis drug Market By Regions: Market Share (%), 2019
Figure 6.2 Global Tuberculosis drug Market Size, By Region: Revenue($m), CAGR (%), 2019-2030
Figure 6.3 Global Tuberculosis drug Market Forecast: Revenue ($m) and AGR (%), 2019-2030
Figure 6.4 Global Tuberculosis Drugs Market By Region: Revenues ($m), 2019
Figure 6.5 Global Tuberculosis Drugs Market By Region: Revenues ($m), 2030
Figure 6.6 Global Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030
Figure 6.7 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2019
Figure 6.8 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2024
Figure 6.9 Global Tuberculosis Drugs Market By Region: Market Shares (%), 2030
Figure 6.10 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019
Figure 6.11 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030
Figure 6.12 North America Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030
Figure 6.13 U.S. Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.14 Canada Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.15 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019
Figure 6.16 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030
Figure 6.17 EUROPE Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.18 Germany Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.19 France Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.20 Italy Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.21 Spain Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.22 United Kingdom Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.23 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019
Figure 6.24 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030
Figure 6.25 Latin America Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030
Figure 6.26 Brazil Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.27 Mexico Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.28 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019
Figure 6.29 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030
Figure 6.30 Middle East & Africa Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030
Figure 6.31 South Africa Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.32 Nigeria Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.33 Tuberculosis Drugs Market By Countries: Revenues ($m), 2019
Figure 6.34 Tuberculosis Drugs Market By Countries: Revenues ($m), 2030
Figure 6.35 Asia and Asia Pacific Tuberculosis Drugs Market By Country/Region: Revenues ($M), 2019-2030
Figure 6.36 India Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.37 China Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 6.38 Japan Tuberculosis Drugs Market Forecast: Revenues ($m) and AGR(%), 2019-2030
Figure 7.1 First Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Figure 7.2 Second Line Tuberculosis Treatment Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Figure 7.3 Tuberculosis Drugs Market By Therapies: Revenues ($m), 2019
Figure 7.4 Tuberculosis Drugs Market By Therapies: Revenues ($m), 2030
Figure 7.5 Tuberculosis Treatment Isoniazid Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Figure 7.6 Tuberculosis Treatment Rifampin Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Figure 7.7 Tuberculosis Treatment Other Drugs Market Forecast: Revenues ($m), AGR (%), and CAGR (%), 2019-2030
Figure 8.1 Johnson & Johnson: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Figure 8.2 Lupin: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Figure 8.3 Macleods Pharmaceuticals Limited: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Figure 8.4 Pfizer: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Figure 8.5 Otsuka Pharmaceuticals: Revenue Forecast, Revenues ($m), AGR (%), and CAGR (%), 2020-2025
Figure 9.1 Global Tuberculosis drugs Market Revenue ($million): 2019, 2025 and 2030
Figure 9.2 Leading Regional Markets Revenue ($million): 2019, 2025, and 2030
